Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors—A retrospective analysis

Haemophilia

Volumn 24, Issue 2, 2018, Pages 245-252

  Carcao, M ^a   Shapiro, A ^b   Staber, J M ^c   Hwang, N ^d   Druzgal, C ^e   Lieuw, K ^f   Belletrutti, M ^g   Thornburg, C D ^h   Ahuja, S P ⁱ   Morales Arias, J ^j   Dumont, J ^j   Miyasato, G ^k   Tsao, E ^j   Jain, N ^j   Pipe, S W ^l  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^c UNIVERSITY OF IOWA CHILDREN S HOSPITAL   (United States)

^d Center for Inherited Blood Disorders   (United States)

^e UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^f WALTER REED ARMY MEDICAL CENTER   (United States)

^g STOLLERY CHILDREN S HOSPITAL   (Canada)

^h RADY CHILDREN'S HOSPITAL   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY   (United States)

^j Bioverativ Inc   (United States)

^k Trinity Partners LLC   (United States)

^l UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

haemophilia A; immune tolerance induction; inhibitor; recombinant factor VIII Fc fusion protein; rescue therapy; retrospective chart review

Indexed keywords

BLOOD CLOTTING FACTOR 8; FACTOR VIII-FC FUSION PROTEIN; FUSION PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

CHILD; CLINICAL TRIAL; HEMOPHILIA A; HUMAN; INFANT; MULTICENTER STUDY; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

CHILD; CHILD, PRESCHOOL; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; INFANT; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES;

EID: 85041833755     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13413     Document Type: Article

References (41)

1. Mannucci PM, Tuddenham EG. The hemophilias–from royal genes to gene therapy. N Engl J Med. 2001;344:1773-1779.
2. Lieuw K. Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? J Blood Med. 2017;8:67-73.
3. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;379:1447-1456.
4. Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377:819-828.
5. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet (London, England). 2016;388:187-197.
6. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109:4648-4654.
7. Darby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost. 2004;2:1047-1054.
8. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007;13(Suppl 1):1-22.
9. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809-818.
10. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003;9:436-463.
11. Coppola A, Margaglione M, Santagostino E, et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost. 2009;7:1809-1815.
12. Gringeri A, Musso R, Mazzucconi MG, et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia. 2007;13:373-379.
13. Hay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119:1335-1344.
14. Haya S, Lopez MF, Aznar JA, Batlle J; Spanish Immune Tolerance Group. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia. 2001;7:154-159.
15. Jimenez-Yuste V, Oldenburg J, Rangarajan S, Kurth MH, Bozzo J, Santagostino E. Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors. Haemophilia. 2016;22:e71-e74.
16. Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, et al. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. Haemophilia. 2016;22:87-95.
17. Nakar C, Manco-Johnson MJ, Lail A, et al. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres. Haemophilia. 2015;21:365-373.
18. Oldenburg J, Jimenez-Yuste V, Peiro-Jordan R, Aledort LM, Santagostino E. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate. Haemophilia. 2014;20:83-91.
19. DiMichele DM, Kroner BL; North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost. 2002;87:52-57.
20. Antun A, Monahan PE, Manco-Johnson MJ, et al. Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study. J Thromb Haemost. 2015;13:1980-1988.
21. Valentino LA, Kempton CL, Kruse-Jarres R, et al. US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors. Haemophilia. 2015;21:559-567.
22. Walsh CE, Jimenez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. Thromb Haemost. 2016;116(Suppl 1):S10-S17.
23. Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123:317-325.
24. Shapiro AD, Mahlangu JN, Perry D, et al. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Haemophilia. 2017;23:392-399.
25. Nolan B, Mahlangu J, Perry D, et al. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016;22:72-80.
26. Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015;13:967-977.
27. Malec LM, Journeycake J, Ragni MV. Extended half-life factor VIII for immune tolerance induction in haemophilia. Haemophilia. 2016;22:e552-e554.
28. De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood. 2008;112:3303-3311.
29. Gupta N, Culina S, Meslier Y, et al. Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance. Sci Transl Med. 2015;7:275ra21.
30. Georgescu MLT, Sponagle K, Hebert K, et al. Factor VIII tolerance induction in haemophilia a mice via transplacental transfer of recombinant factor VIII Fc. J Thromb Haemost. 2015;13:1-997.
31. Krishnamoorthy S, Liu T, Drager D, et al. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. Cell Immunol. 2016;301:30-39.
32. Kis-Toth K, Simpson A, Henry K, Loh C. Immunology studies on recombinant factor VIII Fc fusion protein. Res Pract Thromb Haemost. 2017;1(Suppl 1):1-1451.
33. Jimenez-Yuste V, Oldenburg J, Rangarajan S, Peiro-Jordan R, Santagostino E. Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study. Haemophilia. 2016;22:859-865.
34. Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med. 2017;6:46-64.
35. Su JZJ, Buckley B, Rising T, Hou Q, Jain N. The immune tolerance induction factor utilizations and costs for the management of male hemophilia-A patients who developed inhibitors. Am Soc Hematol. 2016;128:P4758.
36. Mariani G, Kroner B; Immune Tolerance Study Group. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica. 2001;86:1186-1193.
37. Minno GD, Santagostino E, Pratt K, Königs C. New predictive approaches for ITI treatment. Haemophilia. 2014;20:27-43.
38. Kempton CL, White GC 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood. 2009;113:11-17.
39. Callaghan MU, Rajpurkar M, Chitlur M, Warrier I, Lusher J. Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans? Haemophilia. 2011;17:483-489.
40. Groomes CL, Gianferante DM, Crouch GD, Parekh DS, Scott DW, Lieuw K. Reduction of factor VIII inhibitor titers during immune tolerance induction with recombinant factor VIII-Fc fusion protein. Pediatr Blood Cancer. 2016;63:922-924.
41. Su JZJ, Buckley B, Hou Q, Jain N. Utilizations and costs of bypass therapies for the management of hemophilia A patients with inhibitors. Haemophilia. 2017;23:87-88.